Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Year: 2025
Type: other
Abstract: Supplemental Figure S3. A, Efficacy of anti-CLDN6 mouse antibodies in CLDN6 positive OV90 ovarian cancer cell line xenografts. B, Efficacy in CLDN6 positive UMUC4 bladder cancer cell line xenografts. C, No efficacy in CLDN6 negative M202 melanoma cell line xenografts. All antibodies are dosed at 10 mg/kg QW IV in each study. Errors bars represent SEM of 8 replicate animals per group.
Authors: Martina S.J. McDermott, Neil A. O'Brien, Benjamin Hoffstrom, KeWei Gong, Ming Lu, Jun Zhang, Tong Luo, Min Liang, Weiping Jia, Jenny J. Hong, Kevin Chau, Simon Davenport, Bin Xie, Michael F. Press, Richard Panayiotou, Abram Handly-Santana, Joan S. Brugge, Leonard Presta, John Glaspy, Dennis J. Slamon
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416672178